Related Experiment Video
Updated: Jun 8, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
Formulation composition of botulinum toxins in clinical use
1Biologicals Science and Technology, Ipsen Biopharm Limited, Wrexham, UK. andy.pickett@ipsen.com
Abstract:
The use of botulinum toxin (BoNT) has now become the treatment of choice for a range of debilitating neuromuscular diseases and for aesthetic medicine. BoNT products are licensed as prescription-only medicines by the health authorities of each country in which they are approved. The authors describe here the current status with regard to BoNT formulations and detail more precisely what is in each product. These data have been presented previously, in a fragmented way, in papers that discuss characteristics of the BoNT products but not the formulations in detail. This information is essential for clinicians in order to enable informed decisions about which products they wish to use clinically. The authors have also examined developments that are either in progress or likely to occur, based on currently available information.
More Related Videos
Related Concept Videos
Botulism
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Bacterial Toxins
Tetanus
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Production of Biopesticides

